次级免疫抑制剂在难治性免疫检查点抑制剂相关肝毒性中的应用
The use of secondary-immunosuppressants in refractory immune checkpoint inhibitor-related hepatotoxicity
投稿时间:2026-07-01  修订日期:2026-10-12
DOI:
中文关键词:  次级免疫抑制剂  免疫检查点抑制剂  肝毒性  临床应用
英文关键词:secondary-immunosuppressants  immune checkpoint inhibitor  hepatotoxicity  clinic application
基金项目:无
作者单位邮编
包恩达 浙江中医药大学第四临床医学院 310002
刘贝贝 浙江中医药大学第四临床医学院 
张珂* 杭州市肿瘤医院 310002
邓清华 杭州市肿瘤医院 
摘要点击次数: 36
全文下载次数: 4
中文摘要:
      免疫检查点抑制剂(immune checkpoint inhibitor, ICI)相关肝毒性是现如今抗肿瘤治疗中的管理难点之一,约1/3的3级以上肝毒性的病例对一线类固醇治疗应答不足,需要启动次级免疫抑制剂。本文系统检索了PubMed数据库至2026年7月份的文献,共纳入78例使用次级免疫抑制剂治疗的难治性ICI肝毒性患者。汇总分析显示,吗替麦考酚酯(mycophenolate mofetil ,MMF)是最常用的药物(54/78,69.2%),可评估病例的生化复常率为80.9%;托珠单抗单药(8例)复常率50.0%,但中位复常时间更短(21天 vs 62天);联合治疗(MMF+托珠单抗或他克莫司)在9例可评估病例中均实现复常。英夫利昔单抗因潜在肝毒性,主要指南不推荐作为常规二线选择。当前证据以回顾性研究为主,次级免疫抑制剂的启动时机、最佳剂量和疗程仍缺乏前瞻性数据支持。
英文摘要:
      Immune checkpoint inhibitor (ICI)-related hepatotoxicity remains one of the management challenges in current oncologic therapy. Approximately one-third of patients with grade 3 or higher liver toxicity show inadequate response to first-line corticosteroid treatment and require secondary immunosuppressive agents. This study systematically reviewed literature from database including PubMed up to July 2026, identifying 78 patients with refractory ICI-induced hepatotoxicity treated with secondary immunosuppressants. The pooled analysis revealed that mycophenolate mofetil (MMF) was the most commonly used agent (54/78, 69.2%), achieving a biochemical normalization rate of 80.9% in evaluable cases. Tocilizumab monotherapy (n=8) had a normalization rate of 50.0%, but with a shorter median time to normalization (21 days vs. 62 days). Combination therapies (MMF plus tocilizumab or tacrolimus) led to normalization in all 9 evaluable cases. Infliximab is not recommended as a standard second-line option due to its potential hepatotoxicity, according to major guidelines. Current evidence is primarily retrospective, and there remains insufficient prospective data on the optimal timing, dosage, and duration of secondary immunosuppressive therapy.
在线阅读     查看/发表评论  下载PDF阅读器